Familial Isolated Hypoparathyroidism (FIH) Cell Models for Research

Familial Isolated Hypoparathyroidism (FIH) is a rare genetic disorder characterized by isolated hypoparathyroidism without other developmental anomalies. The exact prevalence is unknown, but it is estimated to affect 1 in 100,000 individuals. The condition can present in infancy or later in life, with symptoms due to hypocalcemia, including neuromuscular irritability, seizures, and cataracts. Long-term complications include basal ganglia calcification and renal insufficiency. The clinical impact is significant, requiring lifelong calcium and vitamin D supplementation. According to the National Institutes of Health (NIH), FIH accounts for a small fraction of hypoparathyroidism cases, with most being acquired. The genetic basis is heterogeneous, involving mutations in genes such as GCM2, PTH, and CASR. Early diagnosis and management are crucial to prevent complications.

FIH serves as an excellent model for studying parathyroid gland development and calcium homeostasis. The disease is caused by mutations in a limited set of genes, making it amenable to genetic manipulation in cell lines. Public datasets, such as those from ClinVar and the Human Gene Mutation Database, provide curated information on pathogenic variants. Open questions include the precise molecular mechanisms by which GCM2 mutations impair parathyroid development, and how CASR mutations alter calcium sensing. Gene-edited cell models can help answer these questions by allowing functional validation of specific variants in a controlled environment.

FIH is not a cancer, but the molecular pathways involved in parathyroid development are critical. The main pathways include:

• • GCM2 transcription factor pathway: GCM2 is a master regulator of parathyroid development. Mutations can lead to haploinsufficiency or dominant-negative effects, disrupting parathyroid gland formation.
• • Calcium-sensing receptor (CASR) pathway: CASR is a G-protein-coupled receptor that regulates PTH secretion in response to extracellular calcium. Activating mutations cause hypoparathyroidism by suppressing PTH release.
• • PTH signaling pathway: Mutations in the PTH gene itself can lead to defective PTH synthesis or secretion.
• • Other transcription factors: Genes such as GATA3 and TBX1 are involved in parathyroid development, but mutations in these are associated with syndromic forms, not isolated hypoparathyroidism.

Data from ClinVar and literature. Frequencies are approximate and vary among populations.

The deregulated signaling networks in FIH include:

• • Calcium-sensing network: CASR activation leads to inhibition of PTH secretion via Gq/11 and Gi pathways, affecting intracellular calcium and MAPK signaling.
• • Transcriptional network: GCM2 regulates the expression of PTH and other parathyroid-specific genes, such as CASR and GATA3. Loss of GCM2 disrupts this network.
• • Developmental signaling: Pathways like WNT and SHH are involved in parathyroid development, but their role in FIH is less clear. However, GCM2 interacts with these pathways during embryogenesis.

Organoids are three-dimensional structures that recapitulate parathyroid tissue architecture and function. They can be generated from patient-derived induced pluripotent stem cells (iPSCs) and are useful for studying disease mechanisms and drug responses.

• • Gcm2 knockout mice: These mice lack parathyroid glands and exhibit hypoparathyroidism, making them a valuable model for studying the role of GCM2 in development.
• • Casr activating mutation knock-in mice: These mice have increased calcium sensitivity and reduced PTH secretion, mimicking FIH.
• • Pth knockout mice: These mice have no PTH and exhibit hypocalcemia, but they are not a model of FIH specifically.
• • Induced models: Chemical induction is not commonly used for FIH, as the disease is genetic.

Gene-edited cell models are essential for functional studies of FIH-associated mutations. CRISPR-Cas9 technology allows the creation of isogenic cell lines with specific mutations in genes like GCM2, CASR, and PTH. For example:

• • GCM2 knockout cell lines: These can be used to study the loss of GCM2 function and its impact on downstream gene expression.
• • CASR activating mutation knock-in cell lines: These can be used to study the effect of increased calcium sensitivity on PTH secretion.
• • PTH mutant cell lines: These can be used to study the effect of PTH mutations on protein synthesis and secretion.

Commercially available, sequence-verified gene-edited cell lines accelerate research by providing consistent and reproducible models. These models are crucial for drug discovery and functional genomics.

Gene-edited cells are used to validate the functional impact of genetic variants identified in FIH patients. For example, a GCM2 knockout cell line can be used to assess the expression of PTH and other target genes. Similarly, a CASR knock-in cell line with an activating mutation can be used to measure intracellular calcium responses and PTH secretion. These models help confirm causality and provide insights into disease mechanisms.

Isogenic cell lines with specific mutations can be used in high-throughput screening to identify compounds that modulate PTH secretion or calcium sensing. For example, a CASR activating mutation cell line can be used to screen for negative allosteric modulators that reduce calcium sensitivity. Additionally, gene-edited cells can be used to study resistance to existing therapies, such as PTH replacement, by introducing mutations that affect the PTH receptor.

CRISPR-based synthetic lethality screens can identify genes that are essential for the survival of cells with specific FIH mutations. For example, in GCM2 knockout cells, synthetic lethal partners could be potential drug targets. Additionally, gene-edited cells can be used to identify biomarkers of disease progression or response to therapy by analyzing gene expression profiles.